Xinhua Li , Yuanlong Zhang , Leiqing Chen , Xiao Xu , Xiaohong Ma , Shuying Lou , Ziqiang Zou , Chenjing Wang , Bing Jiang , Yunrui Cai , Yu Qi , Yiyuan Xi , Min Zhao , Pengcheng Yan
{"title":"Actichinone, a new ursane triterpenoid from Actinidia chinensis roots, ameliorates NAFLD via the AMPK and NF-κB pathways","authors":"Xinhua Li , Yuanlong Zhang , Leiqing Chen , Xiao Xu , Xiaohong Ma , Shuying Lou , Ziqiang Zou , Chenjing Wang , Bing Jiang , Yunrui Cai , Yu Qi , Yiyuan Xi , Min Zhao , Pengcheng Yan","doi":"10.1016/j.ejphar.2025.177276","DOIUrl":null,"url":null,"abstract":"<div><div>A new ursane triterpenoid, actichinone (3-oxo-2<em>α</em>,24-dihydroxyurs-12-en-28-oic acid, <strong>1</strong>), was isolated from the roots of a kiwi plant <em>Actinidia chinensis</em> Planch, together with 18 known triterpenoids (<strong>2</strong>–<strong>19</strong>). The structure of actichinone (<strong>1</strong>) was established by extensive spectroscopic analysis. Actichinone (<strong>1</strong>) showed the most potent lipid-lowering activity in the oleic acid (OA)-induced primary mouse hepatocytes and the structure-activity relationships (SARs) were analyzed. Chemical semi-synthesis of actichinone (<strong>1</strong>) was achieved by selective oxidation of the major compound <strong>2</strong>. Actichinone (<strong>1</strong>) exhibited significant alleviation of non-alcoholic fatty liver disease (NAFLD) in a high-fat with methionine and choline deficiency diet (HFMCD)-fed mice model, by regulating lipid accumulation and inflammatory response probably via the AMPK/SREBP-1c/PPAR-<em>α</em> and IKK/I<em>κ</em>B/NF-<em>κ</em>B signaling pathways. This study provides a promising lead compound and a new insight into the development of novel anti-NAFLD agents based on the pentacyclic triterpenoid family, and is expected to promote the high value-added comprehensive application of the <em>A. chinensis</em> plants.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"990 ","pages":"Article 177276"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299925000299","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
A new ursane triterpenoid, actichinone (3-oxo-2α,24-dihydroxyurs-12-en-28-oic acid, 1), was isolated from the roots of a kiwi plant Actinidia chinensis Planch, together with 18 known triterpenoids (2–19). The structure of actichinone (1) was established by extensive spectroscopic analysis. Actichinone (1) showed the most potent lipid-lowering activity in the oleic acid (OA)-induced primary mouse hepatocytes and the structure-activity relationships (SARs) were analyzed. Chemical semi-synthesis of actichinone (1) was achieved by selective oxidation of the major compound 2. Actichinone (1) exhibited significant alleviation of non-alcoholic fatty liver disease (NAFLD) in a high-fat with methionine and choline deficiency diet (HFMCD)-fed mice model, by regulating lipid accumulation and inflammatory response probably via the AMPK/SREBP-1c/PPAR-α and IKK/IκB/NF-κB signaling pathways. This study provides a promising lead compound and a new insight into the development of novel anti-NAFLD agents based on the pentacyclic triterpenoid family, and is expected to promote the high value-added comprehensive application of the A. chinensis plants.
期刊介绍:
The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems.
The scope includes:
Behavioural pharmacology
Neuropharmacology and analgesia
Cardiovascular pharmacology
Pulmonary, gastrointestinal and urogenital pharmacology
Endocrine pharmacology
Immunopharmacology and inflammation
Molecular and cellular pharmacology
Regenerative pharmacology
Biologicals and biotherapeutics
Translational pharmacology
Nutriceutical pharmacology.